A Real-World Survey of Health Inequalities as Drivers for Burden on Male Hemophilia Patients in the US, EU5, and Asia
Author(s)
Sheena Thakkar, BS, MPH1, Nathaniel Posner, MPH2, Cynthia Khanji3, Rabiyah Sahar4, Chris Blazos, M5, Sophie Lai, M5, Ella Morton, M5, Nathan Ball, M5.
1Director, Value & Evidence, Pfizer Inc., Acton, MA, USA, 2Pfizer, Inc., New York, NY, USA, 3Pfizer Canada, Lorraine, QC, Canada, 4Adelphi Real World, United Kingdom, 5Adelphi Real World, London, United Kingdom.
1Director, Value & Evidence, Pfizer Inc., Acton, MA, USA, 2Pfizer, Inc., New York, NY, USA, 3Pfizer Canada, Lorraine, QC, Canada, 4Adelphi Real World, United Kingdom, 5Adelphi Real World, London, United Kingdom.
OBJECTIVES: To investigate health care resource utilization, caregiver utilization, and risk of mortality among male hemophilia patients.
METHODS: Data were drawn from the Adelphi Real World Disease Specific Programme™, a cross-sectional survey with retrospective data collection of physicians and male patients with hemophilia (PwH) A and B in France, Germany, Italy, Spain, the United Kingdom (EU5), the United States (US) and Japan, Saudi Arabia (KSA) and India (Asia) (July 2023-October 2024). Physicians reported data on insurance, consultations, caregiver support, and mortality risks. Analyses were descriptive.
RESULTS: Overall, n=285 physicians provided data for n=2139 PwH (US; n=438, EU5; n=1078, Asia; n=623). Mean (SD) patient age was 26.9 (15.3) years, 79.9% of patients in the US, 81.4% EU5 and 65.2% Asia ≥ 18 years. In the US, EU5 and Asia, 6.4%, 6.7% and 10.3% of PwH were not receiving a prophylactic.
Within US/EU5, 100.0% of PwH had insurance, compared to 53.7% in Asia. Physicians reported 60.7% of US PwH, 83.5% EU5 and 53.3% Asia had been seen at least once in a hemophilia treatment center, with mean (SD) 4.0 (3.5) consultations in US, 7.5 (15.4) EU5 and 7.8 (8.3) Asia with any healthcare professional, the year prior to survey.Physicians perceived increased risk of mortality “moderately”/ “significantly” for 30.6% of PwH in US, 20.5% EU5 and 60.4% Asia. At time of survey, caregiver support was required for 38.2%, 39.4% and 58.3% of PwH ≥ 18 years in US, EU5 and Asia, respectively.
CONCLUSIONS: Physicians reported approximately half of PwH in Asia had no insurance and were never seen in an HTC. PwH in Asia experienced a high perceived risk of mortality. Less adult PwH in the US/EU5 required a caregiver than in Asia. This indicates that decreased insurance and HTC usage are potential drivers of burden in hemophilia, highlighting the need to address health inequalities.
METHODS: Data were drawn from the Adelphi Real World Disease Specific Programme™, a cross-sectional survey with retrospective data collection of physicians and male patients with hemophilia (PwH) A and B in France, Germany, Italy, Spain, the United Kingdom (EU5), the United States (US) and Japan, Saudi Arabia (KSA) and India (Asia) (July 2023-October 2024). Physicians reported data on insurance, consultations, caregiver support, and mortality risks. Analyses were descriptive.
RESULTS: Overall, n=285 physicians provided data for n=2139 PwH (US; n=438, EU5; n=1078, Asia; n=623). Mean (SD) patient age was 26.9 (15.3) years, 79.9% of patients in the US, 81.4% EU5 and 65.2% Asia ≥ 18 years. In the US, EU5 and Asia, 6.4%, 6.7% and 10.3% of PwH were not receiving a prophylactic.
Within US/EU5, 100.0% of PwH had insurance, compared to 53.7% in Asia. Physicians reported 60.7% of US PwH, 83.5% EU5 and 53.3% Asia had been seen at least once in a hemophilia treatment center, with mean (SD) 4.0 (3.5) consultations in US, 7.5 (15.4) EU5 and 7.8 (8.3) Asia with any healthcare professional, the year prior to survey.Physicians perceived increased risk of mortality “moderately”/ “significantly” for 30.6% of PwH in US, 20.5% EU5 and 60.4% Asia. At time of survey, caregiver support was required for 38.2%, 39.4% and 58.3% of PwH ≥ 18 years in US, EU5 and Asia, respectively.
CONCLUSIONS: Physicians reported approximately half of PwH in Asia had no insurance and were never seen in an HTC. PwH in Asia experienced a high perceived risk of mortality. Less adult PwH in the US/EU5 required a caregiver than in Asia. This indicates that decreased insurance and HTC usage are potential drivers of burden in hemophilia, highlighting the need to address health inequalities.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH7
Topic
Epidemiology & Public Health, Health Technology Assessment, Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)